Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Feb;37(2):125–128. doi: 10.1111/j.1365-2125.1994.tb04251.x

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

P E Rolan 1
PMCID: PMC1364588  PMID: 8186058

Full text

PDF
125

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons L. J., Rowland M. Kinetics of drug displacement interactions. J Pharmacokinet Biopharm. 1981 Apr;9(2):181–190. doi: 10.1007/BF01068081. [DOI] [PubMed] [Google Scholar]
  2. Aggeler P. M., O'Reilly R. A., Leong L., Kowitz P. E. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967 Mar 2;276(9):496–501. doi: 10.1056/NEJM196703022760904. [DOI] [PubMed] [Google Scholar]
  3. Banfield C., O'Reilly R., Chan E., Rowland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol. 1983 Dec;16(6):669–675. doi: 10.1111/j.1365-2125.1983.tb02239.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bjornsson T. D., Meffin P. J., Swezey S. E., Blaschke T. F. Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. J Pharmacol Exp Ther. 1979 Sep;210(3):322–326. [PubMed] [Google Scholar]
  5. Bjornsson T. D., Meffin P. J., Swezey S., Blaschke T. F. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. J Pharmacol Exp Ther. 1979 Sep;210(3):316–321. [PubMed] [Google Scholar]
  6. Brodie B. B. Displacement of one drug by another from carrier or receptor sites. Proc R Soc Med. 1965 Nov;58(11 Pt 2):946–955. [PMC free article] [PubMed] [Google Scholar]
  7. CHRISTENSEN L. K., HANSEN J. M., KRISTENSEN M. SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS. Lancet. 1963 Dec 21;2(7321):1298–1301. doi: 10.1016/s0140-6736(63)90847-x. [DOI] [PubMed] [Google Scholar]
  8. FOX S. L. POTENTIATION OF ANTICOAGULANTS CAUSED BY PYRAZOLE COMPOUNDS. JAMA. 1964 Apr 20;188:320–321. doi: 10.1001/jama.1964.03060290124046. [DOI] [PubMed] [Google Scholar]
  9. Faed E. M. Protein binding of drugs in plasma, interstitial fluid and tissues: effect on pharmacokinetics. Eur J Clin Pharmacol. 1981;21(1):77–81. doi: 10.1007/BF00609592. [DOI] [PubMed] [Google Scholar]
  10. Gibaldi M., Levy G., McNamara P. J. Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther. 1978 Jul;24(1):1–4. doi: 10.1002/cpt19782411. [DOI] [PubMed] [Google Scholar]
  11. Griner P. F., Raisz L. G., Rickles F. R., Wiesner P. J., Odoroff C. L. Chloral hydrate and warfarin interaction: clinical significance. Ann Intern Med. 1971 Apr;74(4):540–543. doi: 10.7326/0003-4819-74-4-540. [DOI] [PubMed] [Google Scholar]
  12. Hansen J. M., Christensen L. K. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 1977 Jan;13(1):24–34. doi: 10.2165/00003495-197713010-00003. [DOI] [PubMed] [Google Scholar]
  13. Koch-Weser J., Sellers E. M. Binding of drugs to serum albumin (first of two parts). N Engl J Med. 1976 Feb 5;294(6):311–316. doi: 10.1056/NEJM197602052940605. [DOI] [PubMed] [Google Scholar]
  14. Liegler D. G., Henderson E. S., Hahn M. A., Oliverio V. T. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849–857. doi: 10.1002/cpt1969106849. [DOI] [PubMed] [Google Scholar]
  15. MacKichan J. J. Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet. 1984 Jan;9 (Suppl 1):32–41. doi: 10.2165/00003088-198400091-00005. [DOI] [PubMed] [Google Scholar]
  16. McElnay J. C., D'Arcy P. F. Protein binding displacement interactions and their clinical importance. Drugs. 1983 May;25(5):495–513. doi: 10.2165/00003495-198325050-00003. [DOI] [PubMed] [Google Scholar]
  17. O'Reilly R. A., Goulart D. A. Comparative interaction of sulfinpyrazone and phenylbutazone with racemic warfarin: alteration in vivo of free fraction of plasma warfarin. J Pharmacol Exp Ther. 1981 Dec;219(3):691–694. [PubMed] [Google Scholar]
  18. O'Reilly R. A. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med. 1980 Jan 3;302(1):33–35. doi: 10.1056/NEJM198001033020106. [DOI] [PubMed] [Google Scholar]
  19. O'Reilly R. A., Trager W. F., Motley C. H., Howald W. Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest. 1980 Mar;65(3):746–753. doi: 10.1172/JCI109722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Perucca E., Hebdige S., Frigo G. M., Gatti G., Lecchini S., Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther. 1980 Dec;28(6):779–789. doi: 10.1038/clpt.1980.235. [DOI] [PubMed] [Google Scholar]
  21. Pond S. M., Birkett D. J., Wade D. N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):573–579. doi: 10.1002/cpt1977225part1573. [DOI] [PubMed] [Google Scholar]
  22. Sellers E. M., Koch-Weser J. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci. 1971 Jul 6;179:213–225. doi: 10.1111/j.1749-6632.1971.tb46901.x. [DOI] [PubMed] [Google Scholar]
  23. Sellers E. M., Koch-Weser J. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med. 1970 Oct 15;283(16):827–831. doi: 10.1056/NEJM197010152831601. [DOI] [PubMed] [Google Scholar]
  24. Sellers E. M. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology. 1979;18(5):225–227. doi: 10.1159/000137256. [DOI] [PubMed] [Google Scholar]
  25. Stewart C. F., Fleming R. A., Germain B. F., Seleznick M. J., Evans W. E. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum. 1991 Dec;34(12):1514–1520. doi: 10.1002/art.1780341207. [DOI] [PubMed] [Google Scholar]
  26. Tillement J. P., Zini R., Mattei C., Singlas E. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol. 1973 Jun;6(1):15–18. doi: 10.1007/BF00561795. [DOI] [PubMed] [Google Scholar]
  27. Toon S., Low L. K., Gibaldi M., Trager W. F., O'Reilly R. A., Motley C. H., Goulart D. A. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986 Jan;39(1):15–24. doi: 10.1038/clpt.1986.3. [DOI] [PubMed] [Google Scholar]
  28. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES